Huperzine A is extracted from a small Chinese plant, Huperzia serrata. It inhibits the enzyme breaking down acetylcholine, a chemical messenger of memory, just like some Alzheimer's medicines. What do trials actually show in patients and healthy people? Which doses were studied, and what precautions matter? The evidence without shortcuts.
Key takeaways
- Huperzine A reversibly inhibits acetylcholinesterase, the enzyme breaking down acetylcholine in the brain.
- Trials mainly involved Alzheimer's patients; Cochrane considers their quality insufficient for any recommendation.
- In healthy people, data are limited to a small 1999 Chinese study in secondary-school pupils.
- Possible cholinergic effects, including slowing the heart, and drug interactions: medical advice is needed with medication. In 2024, the Dutch public health institute RIVM deemed these supplements harmful and advised against consumption.
What is huperzine A?
Huperzine A is an alkaloid, a plant-derived nitrogen-containing molecule. Chinese researchers isolated it in 1986 from Huperzia serrata, a clubmoss-family plant called Qian Ceng Ta in traditional Chinese medicine.
It is not a nutrient: the body does not need it to function. Interest comes entirely from its pharmacological action, explaining both its studied effects and precautions.
How does huperzine A act on the brain?
Acetylcholine transmits information between certain neurons, particularly attention and memory circuits. After transmission, it is destroyed by acetylcholinesterase. Huperzine A reversibly blocks this enzyme: acetylcholine remains available longer.
This is the principle of donepezil, rivastigmine and galantamine, prescribed for Alzheimer's disease. A review by Chinese researchers suggests huperzine A may cross from blood to brain more effectively than several of these drugs and act longer. Effects on other targets, such as NMDA receptors, are described in the laboratory; their human relevance remains to be established.
What do patient trials show?
Most were conducted in China in Alzheimer's patients. They are numerous but often small and methodologically weak.
| Analysis | Participants | Result |
|---|---|---|
| Cochrane review, 2008 | 6 trials, 454 patients (Alzheimer's) | MMSE +2.8 points, only one trial of sufficient quality |
| Meta-analysis, 2013 | 20 trials, 1,823 patients (Alzheimer's) | Favourable effects, high bias risk |
| US trial, 2011 | 210 patients, 16 weeks | No effect on primary outcome |
| Cochrane review, 2012 | Mild cognitive impairment | No usable trial |
| Cochrane review, 2009 | Vascular dementia | One 14-person trial, no significant effect |
The Cochrane Alzheimer's review
In 2008, Cochrane analysed six randomised trials involving 454 patients. Compared with placebo, huperzine A improved the global cognitive MMSE score by around 2.8 of 30 points and daily independence. But only one trial was sufficiently large and good quality: authors judged evidence insufficient to make a recommendation.
A broader 2013 meta-analysis pooled twenty trials and 1,823 patients aged 50 to 85. It found favourable cognitive and daily-activity effects, but most trials had high bias risk. Authors urged cautious interpretation.
The 2011 US trial
A US trial included 210 patients with mild to moderate Alzheimer's. For at least sixteen weeks, they received placebo or huperzine A at 200 or 400 µg twice daily. The primary 200 µg twice-daily dose had no cognitive effect.
With 400 µg twice daily, an ADAS-Cog cognitive gain of 2.3 points appeared at eleven weeks versus a 0.3-point decline with placebo. At sixteen weeks, the difference was no longer significant.
Mild cognitive impairment and vascular dementia
Two further Cochrane reviews sought trials in these conditions. The first found none usable. The second retained only one fourteen-participant trial with no significant effect. Data are lacking in these situations.
What about healthy people?
Data are very scarce. The most-cited study dates to 1999: 34 matched pairs of Chinese secondary-school pupils complaining of memory received 100 µg twice daily or placebo for four weeks. Their memory quotient reached 115 with huperzine versus 104 with placebo, and Chinese-language grades improved.
This small-sample result, published in a Chinese journal, has not been replicated to our knowledge. We found no rigorous trial evaluating huperzine A in healthy adults or safety beyond a few months.
Half-life: how long does it stay in the body?
Huperzine A is rapidly absorbed: in healthy volunteers, blood concentration peaks in around 60 to 80 minutes. Its elimination half-life, the time to eliminate half the dose, was estimated at around five hours in six volunteers (0.99mg dose) and twelve hours in twelve others (0.4mg).
These two small studies use different calculation models and provide an approximate range rather than a precise value. Clinical trials generally divided daily doses into two intakes.
Which huperzine A doses were studied?
Doses are in micrograms: 1mg equals 1,000 µg. In the twenty trials of the 2013 meta-analysis, doses ranged from 200 to 800 µg daily, averaging around 370 µg, over eight to 36 weeks. The 1999 pupils received 200 µg daily; the highest US trial dose reached 800 µg.
These doses were studied in trials, usually in medically supervised patients: they are not recommendations.
What adverse effects occur?
They mainly follow its mechanism: more acetylcholine also means more cholinergic effects throughout the body. Trials reported nausea, appetite loss, dizziness, vomiting, constipation, insomnia, excitation, thirst, sweating and slowed heart rate (bradycardia).
These were described as mild, with no serious adverse effect reported, but seven of twenty trials reported no adverse-effect information at all. In 2024, RIVM nevertheless judged Huperzia serrata supplements harmful: its assessment found cholinergic effects (excess salivation, abdominal cramps, diarrhoea, muscle weakness, blurred vision) possible even at the recommended dose and advised against use, particularly during pregnancy. Cholinesterase inhibitors are not innocuous: among nearly 20,000 older dementia patients treated with these medicines, syncope hospitalisations were 1.8 times more frequent and bradycardia hospitalisations 1.7 times more frequent than in untreated people.
Interactions and contraindications
Huperzine A can enhance or oppose several medicines. The table summarises situations described in literature.
| Situation | Risk | Action |
|---|---|---|
| Donepezil, rivastigmine, galantamine | Combined cholinergic effects | Do not combine |
| Beta-blockers, some calcium channel blockers | More pronounced bradycardia | Medical advice |
| Dopamine-blocking antipsychotics | Parkinsonian symptoms | Medical advice |
| Anticholinergic medicines | Opposing effects | Medical advice |
| Slow heart rate, conduction disorder | Possible worsening | Avoid |
| Pregnancy, breastfeeding, under 18 | Insufficient safety data | Avoid |
Anticholinergics, such as some urinary incontinence medicines, older antihistamines or tricyclic antidepressants, block acetylcholine. In a study of 5,625 people starting a cholinesterase inhibitor, 37% also received an anticholinergic, a combination authors judged potentially inappropriate.
Leaflets for medicines in the same class mention other precautions: asthma, epilepsy, stomach ulcer or difficulty urinating. Discuss any intake with your doctor in chronic illness, current medication or planned surgery.
Frequently asked questions
Is huperzine A a medicine?
Status varies by country. In China it is registered as a medicine prescribed for Alzheimer's. In the US it is sold as a supplement. No health claim is authorised for huperzine A in the EU: a containing product cannot claim any memory or concentration effect.
Is huperzine A found in food?
No. It comes from a clubmoss-family plant not consumed as food. It occurs only as extract or purified molecule in supplements. This also explains the lack of a dietary reference intake.
Can huperzine A be combined with choline?
This popular combination aims to supply acetylcholine's raw material and slow its breakdown. We found no controlled trial evaluating it in healthy adults. For requirements and sources, see our article on choline.
How long can it be taken?
Patient trials lasted eight to 36 weeks, averaging around fifteen. Beyond that, safety has not been rigorously evaluated. Prolonged use therefore requires medical supervision, especially as heart slowing can go unnoticed.
Should it be taken morning or evening?
No study compared timing. Trials divided doses into two daily intakes. Insomnia and excitation are reported effects: if sleep is disrupted, discuss it with a healthcare professional. Our article on sleep and melatonin reviews sleep disorders.
Capsule or tablet: does form matter?
No study compared huperzine A dosage forms. What matters is actual huperzine A per unit in micrograms, not plant extract weight: one Hexagon® huperzine A 100 µg capsule, for example, contains 100 µg. For capsule, softgel and tablet differences, see our article on dosage forms.
Conclusion
Huperzine A is active, with a mechanism resembling Alzheimer's medicines. Trials, almost all in patients, show possible effects but are insufficient quality, and healthy-person data are nearly absent. Cholinergic effects and interactions require caution, and RIVM has advised against these supplements since 2024. For everyday memory, the best-demonstrated methods lie elsewhere: see ways to improve memory.
Sources
- Liu JS et al. (1986). The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Canadian Journal of Chemistry, 64(4), 837-839. doi:10.1139/v86-137
- Qian ZM, Ke Y (2014). Huperzine A: Is it an Effective Disease-Modifying Drug for Alzheimer's Disease? Frontiers in Aging Neuroscience, 6, 216. doi:10.3389/fnagi.2014.00216
- Wang R, Yan H, Tang XC (2006). Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacologica Sinica, 27(1), 1-26. doi:10.1111/j.1745-7254.2006.00255.x
- Li J et al. (2008). Huperzine A for Alzheimer's disease. Cochrane Database of Systematic Reviews, (2), CD005592. doi:10.1002/14651858.CD005592.pub2
- Yang G et al. (2013). Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS One, 8(9), e74916. doi:10.1371/journal.pone.0074916
- Rafii MS et al. (2011). A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology, 76(16), 1389-1394. doi:10.1212/WNL.0b013e318216eb7b
- Yue J et al. (2012). Huperzine A for mild cognitive impairment. Cochrane Database of Systematic Reviews, 12, CD008827. doi:10.1002/14651858.CD008827.pub2
- Hao Z et al. (2009). Huperzine A for vascular dementia. Cochrane Database of Systematic Reviews, (2), CD007365. doi:10.1002/14651858.CD007365.pub2
- Sun QQ et al. (1999). Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacologica Sinica (Zhongguo Yao Li Xue Bao), 20(7), 601-603. PubMed 10678121
- Qian BC et al. (1995). Pharmacokinetics of tablet huperzine A in six volunteers. Acta Pharmacologica Sinica (Zhongguo Yao Li Xue Bao), 16(5), 396-398. PubMed 8701751
- Li YX et al. (2007). Pharmacokinetics of huperzine A following oral administration to human volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 32(4), 183-187. doi:10.1007/BF03191002
- Memorial Sloan Kettering Cancer Center (2022). Huperzia serrata: professional fact sheet (mechanism, adverse effects, interactions), updated 26 May 2022. mskcc.org
- Gill SS et al. (2009). Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Archives of Internal Medicine, 169(9), 867-873. doi:10.1001/archinternmed.2009.43
- Boudreau DM et al. (2011). Concomitant use of cholinesterase inhibitors and anticholinergics: prevalence and outcomes. Journal of the American Geriatrics Society, 59(11), 2069-2076. doi:10.1111/j.1532-5415.2011.03654.x
- de Heer JA, de Wit-Bos L (2024). Risicobeoordeling van kruidenpreparaten met Huperzia serrata [Risk assessment of preparations containing Huperzia serrata]. RIVM, report 2024-0028. rivm.nl
Food supplements do not replace a varied, balanced diet or a healthy lifestyle. Ask a healthcare professional for advice if you are taking medication, pregnant or breastfeeding.
